Hativ electrocardiogram monitoring on Patients with Chemotherapy

Not Applicable

Recruiting

• Conditions: Neoplasms

• Registration Number: KCT0009198
• Lead Sponsor: Chonnam National University Hospital Hwasun Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Adults aged 19 or older who own a smartphone.
Patients currently taking oral anticancer drugs for solid tumors, who have undergone an electrocardiogram within the past year as per the study enrollment criteria.
(Thyroid cancer/Breast cancer/Lung cancer: Abemaciclib, Alectinib, Capecitabine, Ceritinib, Crizotinib, Ibrutinib, Lapatinib, Lazertinib, Lenvatinib, Lorlatinib, Osimertinib, Ponatinib, Ribociclib, Sorafenib, Sunitinib, Vandetanib, Vemurafenib)

Exclusion Criteria

Individuals with physical disabilities preventing the use of the portable electrocardiogram device, hativ®.
Individuals with intracardiac devices such as pacemakers, ICD, CRT, VAD.
Subjects who are unable to read the informed consent form (illiterate, foreigners, etc.).
Patients deemed inappropriate for participation in the clinical study based on the judgment of the researchers

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnostic rates of clinically significant arrhythmia events over three months

Secondary Outcome Measures

Name	Time	Method
Treatment intervention and timing according to diagnosis